Copyright
©The Author(s) 2021.
World J Stem Cells. Jan 26, 2021; 13(1): 30-48
Published online Jan 26, 2021. doi: 10.4252/wjsc.v13.i1.30
Published online Jan 26, 2021. doi: 10.4252/wjsc.v13.i1.30
Animal model | Treatment | Results | Ref. |
Bleomycin-induced lung fibrosis mouse model | Human ADSC administration | Amelioration of cuboidal alveolar epithelial cell hyperplasia, alveolar duct infiltration, septal thickening and tissue fibrosis. Suppression of epithelial cell apoptosis and reduction of TGF-β expression | Lee et al[47], 2014 |
Aged mouse model of bleomycin-induced lung fibrosis | Single intravenous injection of allogeneic ADSCs | Attenuation of lung and skin fibrosis | Rubio et al[48], 2018 |
Bleomycin-induced lung injury rat model | Intratracheal administration of autologous ADSCs | Prevention of further aggravation of lung damage at day 15 after disease induction | Uji et al[49], 2015 |
Bleomycin-induced lung fibrosis mouse model | Administration of ADSCs from aged and young mice | Decreased pulmonary fibrosis, oxidative stress, and markers of apoptosis only in animals receiving young ADSCs at day 21 after bleomycin instillation | Tashiro et al[50], 2015 |
Bleomycin-induced skin sclerosis model in nude mice | Local subcutaneous injections of human micro-fat enriched with SVF | Decrease in the established dermal fibrosis and increase in local vascularization | Serratrice et al[51], 2014 |
Bleomycin-induced skin sclerosis model in nude mice | Human ADSC-assisted local subcutaneous lipotransfer | Reduced TGF-β1 and type III collagen expression | Chen et al[52], 2018 |
Bleomycin-induced skin fibrosis mouse model | Subcutaneous injection of autologous ADSCs | Amelioration of dermal fibrosis | Chen et al[53], 2017 |
Bleomycin-induced scleroderma and Scl-cGVHD mouse models | Intravenous administration of allogeneic ADSCs | Attenuation of skin and lung fibrosis | Okamura et al[54], 2020 |
Bleomycin-induced skin fibrosis mouse model | Intradermal injection of allogeneic ADSCs | Provision of dendritic cell-derived signals improved survival and effectiveness of therapeutically delivered ADSCs | Chia et al[55], 2016 |
HOCl-induced mouse model of diffuse SSc | Intravenous injection of healthy murine and human ADSCs | Decrease in skin and lung fibrotic and pro-inflammatory markers | Maria et al[56], 2016 |
No. of patients | Follow-up period | Results (face) | Ref. |
1 | - | Autologous fat grafting improved perioral aesthetic appearance and mouth opening | Ho-Asjoe et al[58], 1996 |
20 | 3 mo | Autologous fat grafting increased interincisal distance, oral perimeter and induced skin neovascularization | Del Papa et al[60], 2015 |
14 | 6 mo | Autologous fat grafting improved perioral skin sclerosis, facial pain, mouth opening and sicca syndrome | Sautereau et al[61], 2016 |
7 | 12 mo | Autologous fat grafting improved SSc-related microstomia and microcheilia | Blezien et al[62], 2017 |
16 | 3 mo | Autologous fat transfer significantly improved mouth opening capacity | Gheisari et al[63], 2018 |
1 | - | Autologous fat grafting enriched with PRP improved skin trophicity | Daumas et al[13], 2020 |
6 | 3 mo | The combined use of autologous lipoaspirate and PRP improved buccal rhyme, skin elasticity, and vascularization of the perioral and malar areas | Virzì et al[64], 2017 |
6 | 12 mo | Local injection of autologous ADSCs in combination with a hyaluronic acid solution led to arrest of local disease progression, regression of dyschromia, better sensitivity, increase in skin softening and erythema reduction | Scuderi et al[23], 2013 |
10 | 12 mo | Both autologous fat grafting and ADSC-enriched hyaluronic acid gel improved mouth opening and interincisal distance | Onesti et al[65], 2016 |
62 | 6-53 mo | Autologous ADSC-enriched lipotransfer significantly improved mouth function, facial volumetric appearance and psychological outcome | Almadori et al[3], 2019 |
No. of patients | Follow-up period | Results (hands) | Ref. |
13 | 9.4 to 24.3 mo | Autologous fat implantation led to significant pain relief and decrease in the number, duration, and severity of Raynaud’s phenomenon cold attacks | Bank et al[66], 2014 |
9 | 12 wk | Autologous fat grafting was effective in accelerating the healing process of DUs and led to a significant reduction in hand pain and need of pharmacological therapy | Bene et al[67], 2014 |
15 | 6 mo | Autologous SVF injections led to prompt disappearance of local ischemic pain, rapid DU healing and improvement in nailfold capillaroscopy abnormalities | Del Papa et al[68], 2015 |
38 | 8 wk | Autologous fat grafting induced DU healing, restoration of the capillary bed and a rapid resolution of local ischemic pain | Del Papa et al[14], 2019 |
12 | 6 mo | Injection of autologous SVF proved to be safe, well tolerated and beneficial in terms of pain, grasping capacity, finger edema, Raynaud’s phenomenon, DU outcome and quality of life | Granel et al[69], 2015 |
12 | 12 mo | The effects recorded by Granel et al[69] proved to be long lasting, as they persisted 1 yr after SVF injection | Guillaume-Jugnot et al[70], 2016 |
12 | 22-30 mo | The effects recorded by Granel et al[69] were still very encouraging even at 22 and 30 mo after treatment | Daumas et al[72], 2017 |
1 | - | Autologous SVF subcutaneous injections had beneficial effects on digital necrosis, ulceration, gangrene and impaired wound healing | Song et al[73], 2017 |
- Citation: Rosa I, Romano E, Fioretto BS, Matucci-Cerinic M, Manetti M. Adipose-derived stem cells: Pathophysiologic implications vs therapeutic potential in systemic sclerosis. World J Stem Cells 2021; 13(1): 30-48
- URL: https://www.wjgnet.com/1948-0210/full/v13/i1/30.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v13.i1.30